Statistics from Altmetric.com
For the majority of children who are immunocompromised or who require immunosuppression, their primary diagnosis necessitates a difficult programme of prolonged treatment. In countries with no varicella vaccination, this is compounded by the ever-present and significant threat of chickenpox. Potential exposures must be avoided, causing children to miss school and playgroups whenever chickenpox is at large. Each contact with varicella results in negotiating blood testing to assess their current varicella zoster virus (VZV) status followed by either varicella zoster immunoglobulin (VZIG) therapy or antiviral treatment in hospital or five times a day at home. Immunosuppressive treatment may be interrupted with consequent risk of reduced remission rates, or disease relapse.
Before the availability of VZIG and antiviral agents, the death rate from varicella was around 7% for children being treated for cancer, with 32% having visceral dissemination; children with lymphopenia were at highest risk.1 Since the use of prophylaxis and treatment, deaths from varicella are now very rare.2 However, without careful management of varicella exposure, there remains a risk of severe disseminated disease, with the development of varicella pneumonia, encephalitis, hepatitis, or haemorrhagic complications.3 Despite the best preventive interventions, child deaths still occur.4
The number of immunocompromised children is unknown but is thought to be increasing, including children with primary immunodeficiencies, acquired immunodeficiency and those that are immunosuppressed by treatment including novel biological therapies. This is not a homogenous population; those with impaired T cell function are particularly susceptible to severe varicella.
Although antibody responses to varicella are critical in the control of acute infection, T lymphocyte mediated immunity (comprising both CD4 and CD8 effector and memory T cells) provides the antigen-specific adaptive immunity which stops viral replication and is essential for recovery from …
Competing interests AF undertakes clinical research, advisory work and speaking engagements for all the major vaccine manufacturers including GSK and SP-MSD who market varicella vaccines in Europe. All income generated from these activities is paid to his employers at the University of Bristol and University Hospitals Bristol NHS Foundation Trust. He also undertakes unpaid advisory work concerning vaccines for the UK government and the WHO.
Provenance and peer review Commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.